FDA Issues AbbVie Complete Response Letter for ABBV-951 in Parkinson Disease

Published Date: 27 Jun 2024

In the CRL, the agency cited observations identified during inspection of a third-party manufacturer listed in the NDA. If approved, ABBV-951 would be the first subcutaneous delivery option of carbidopa/levodopa.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

2.

Detecting pancreatic cancer through changes in body composition and metabolism

3.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.

4.

The pandemic had little impact on mental health symptoms.

5.

Men over 75 years old may be significantly more likely to commit suicide if they have cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot